[Prognosis of hematological patients with relapse following high-dose chemotherapy and autologous stem cell transplantation].
A retrospective analysis of the outcome for 283 haematological patients who relapsed after high dose chemotherapy and autologous stem cell transplantation during a five year period from 1989 to 1994 is presented. The patients were treated in accordance with local regimes at 20 Nordic transplantation centers and included patients with acute leukemia (157 patients), multiple myeloma (16 patients) and lymphoma (110 patients). Two hundred and twenty-nine patients with relapse or progressive disease were given chemo- and/or radiotherapy and the response was evaluated after 90 days. Fifty-four patients (24%) obtained a complete remission and 44 patients (19%) partial remission. The overall median survival after relapse was five months. In the group who received salvage treatment the median survival was seven months, and for the 54 patients in complete remission the median survival was 15 months. We found that survival after relapse depends upon primary disease, the time from transplantation to relapse and whether salvage therapy was initiated.
Baggers
J
J
Medicinsk haematologisk afdeling L, Amtssygehuset i Herlev.
Johnsen
H E
HE
D000293:Adolescent; D000328:Adult; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D002648:Child; D002675:Child, Preschool; D003131:Combined Modality Therapy; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D007223:Infant; D007938:Leukemia / Q000175:diagnosis / Q000401:mortality / Q000601:surgery*; D008223:Lymphoma / Q000175:diagnosis / Q000401:mortality / Q000601:surgery*; D008297:Male; D009101:Multiple Myeloma / Q000175:diagnosis / Q000401:mortality / Q000601:surgery*; D009364:Neoplasm Recurrence, Local; D011379:Prognosis; D012189:Retrospective Studies; D016879:Salvage Therapy; D012537:Scandinavian and Nordic Countries / Q000453:epidemiology; D014182:Transplantation, Autologous
D000970:Antineoplastic Agents
Prognosen for haematologiske patienter med relaps efter højdosiskemoterapi og autolog stamcelletransplantation.